Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant 177Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors

Conclusion: In a moderate fraction of GEP-NET patients, with or without liver metastases, whose primary tumor was unresectable because of vascular involvement, the primary tumor converted from unresectable to resectable after 177Lu-DOTATATE therapy, signifying that neoadjuvant PRRT can be considered in such patients. The effective control of symptoms, favorable morphologic and functional imaging response, and durable PFS and OS that we observed after 177Lu-DOTATATE PRRT may lead to less morbidity and mortality in these patients.

Source: Journal of Nuclear Medicine - November 1, 2021 Category: Nuclear Medicine Authors: Parghane, R. V., Bhandare, M., Chaudhari, V., Ostwal, V., Ramaswamy, A., Talole, S., Shrikhande, S. V., Basu, S. Tags: Featured Article of the Month Source Type: research